Filaggrin loss-of-function mutations and incident cancer: a population-based study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Filaggrin loss-of-function mutations and incident cancer : a population-based study. / Skaaby, T; Husemoen, L L N; Thyssen, J P; Meldgaard, M; Thuesen, B H; Pisinger, C; Jørgensen, T; Carlsen, K; Johansen, J D; Menné, T; Szecsi, P B; Stender, S; Linneberg, A.

In: British Journal of Dermatology, Vol. 171, No. 6, 12.2014, p. 1407-1414.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Skaaby, T, Husemoen, LLN, Thyssen, JP, Meldgaard, M, Thuesen, BH, Pisinger, C, Jørgensen, T, Carlsen, K, Johansen, JD, Menné, T, Szecsi, PB, Stender, S & Linneberg, A 2014, 'Filaggrin loss-of-function mutations and incident cancer: a population-based study', British Journal of Dermatology, vol. 171, no. 6, pp. 1407-1414. https://doi.org/10.1111/bjd.12969

APA

Skaaby, T., Husemoen, L. L. N., Thyssen, J. P., Meldgaard, M., Thuesen, B. H., Pisinger, C., ... Linneberg, A. (2014). Filaggrin loss-of-function mutations and incident cancer: a population-based study. British Journal of Dermatology, 171(6), 1407-1414. https://doi.org/10.1111/bjd.12969

Vancouver

Skaaby T, Husemoen LLN, Thyssen JP, Meldgaard M, Thuesen BH, Pisinger C et al. Filaggrin loss-of-function mutations and incident cancer: a population-based study. British Journal of Dermatology. 2014 Dec;171(6):1407-1414. https://doi.org/10.1111/bjd.12969

Author

Skaaby, T ; Husemoen, L L N ; Thyssen, J P ; Meldgaard, M ; Thuesen, B H ; Pisinger, C ; Jørgensen, T ; Carlsen, K ; Johansen, J D ; Menné, T ; Szecsi, P B ; Stender, S ; Linneberg, A. / Filaggrin loss-of-function mutations and incident cancer : a population-based study. In: British Journal of Dermatology. 2014 ; Vol. 171, No. 6. pp. 1407-1414.

Bibtex

@article{137e646cedf24d749c5c4a0ce0f02961,
title = "Filaggrin loss-of-function mutations and incident cancer: a population-based study",
abstract = "BACKGROUND: Loss-of-function mutations in the filaggrin gene (FLG) could have opposing effects on cancer risk, as mutations are associated with both 10{\%} higher serum vitamin D levels, which may protect against cancer, and with impaired skin barrier function, which may lead to higher cancer susceptibility.OBJECTIVES: To investigate the association of the FLG genotype and cancer types in four population-based cohorts.METHODS: A total of 13,376 individuals were genotyped for FLG mutations. Information on cancer was obtained from the Danish Cancer Registry. Persons with a history of cancer at baseline were excluded from prospective analyses.RESULTS: There were 1339 incident cancers (median follow-up 11·4 years). The hazard ratios (HRs) and 95{\%} confidence intervals (CIs) for FLG mutation carriers vs. wild types were: for any cancer (HR 0·95, 95{\%} CI 0·78-1·16), any cancer excluding nonmelanoma skin cancer (NMSC) (HR 1·05, 95{\%} CI 0·84-1·31), head and neck cancer (HR 1·72, 95{\%} CI 0·71-4·15), colorectal cancer (HR 0·82, 95{\%} CI 0·44-1·52), bronchus and lung cancer (HR 1·34, 95{\%} CI 0·77-2·33), breast cancer (HR 0·58, 95{\%} CI 0·30-1·14), uterine cancer (HR 0·42, 95{\%} CI 0·06-3·10), prostate cancer (HR 1·09, 95{\%} CI 0·61-1·94), urinary cancer (HR 1·30, 95{\%} CI 0·51-3·29), malignant melanoma (HR 1·03, 95{\%} CI 0·41-2·58) and NMSC (HR 0·70, 95{\%} CI 0·47-1·05). Among participants aged over 60 years at baseline, we found statistically significant lower risks of all cancers and NMSC among FLG mutation carriers.CONCLUSIONS: The only significant associations between FLG loss-of-function mutations and cancer were in subgroup analyses.",
author = "T Skaaby and Husemoen, {L L N} and Thyssen, {J P} and M Meldgaard and Thuesen, {B H} and C Pisinger and T J{\o}rgensen and K Carlsen and Johansen, {J D} and T Menn{\'e} and Szecsi, {P B} and S Stender and A Linneberg",
note = "{\circledC} 2014 British Association of Dermatologists.",
year = "2014",
month = "12",
doi = "10.1111/bjd.12969",
language = "English",
volume = "171",
pages = "1407--1414",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "6",

}

RIS

TY - JOUR

T1 - Filaggrin loss-of-function mutations and incident cancer

T2 - a population-based study

AU - Skaaby, T

AU - Husemoen, L L N

AU - Thyssen, J P

AU - Meldgaard, M

AU - Thuesen, B H

AU - Pisinger, C

AU - Jørgensen, T

AU - Carlsen, K

AU - Johansen, J D

AU - Menné, T

AU - Szecsi, P B

AU - Stender, S

AU - Linneberg, A

N1 - © 2014 British Association of Dermatologists.

PY - 2014/12

Y1 - 2014/12

N2 - BACKGROUND: Loss-of-function mutations in the filaggrin gene (FLG) could have opposing effects on cancer risk, as mutations are associated with both 10% higher serum vitamin D levels, which may protect against cancer, and with impaired skin barrier function, which may lead to higher cancer susceptibility.OBJECTIVES: To investigate the association of the FLG genotype and cancer types in four population-based cohorts.METHODS: A total of 13,376 individuals were genotyped for FLG mutations. Information on cancer was obtained from the Danish Cancer Registry. Persons with a history of cancer at baseline were excluded from prospective analyses.RESULTS: There were 1339 incident cancers (median follow-up 11·4 years). The hazard ratios (HRs) and 95% confidence intervals (CIs) for FLG mutation carriers vs. wild types were: for any cancer (HR 0·95, 95% CI 0·78-1·16), any cancer excluding nonmelanoma skin cancer (NMSC) (HR 1·05, 95% CI 0·84-1·31), head and neck cancer (HR 1·72, 95% CI 0·71-4·15), colorectal cancer (HR 0·82, 95% CI 0·44-1·52), bronchus and lung cancer (HR 1·34, 95% CI 0·77-2·33), breast cancer (HR 0·58, 95% CI 0·30-1·14), uterine cancer (HR 0·42, 95% CI 0·06-3·10), prostate cancer (HR 1·09, 95% CI 0·61-1·94), urinary cancer (HR 1·30, 95% CI 0·51-3·29), malignant melanoma (HR 1·03, 95% CI 0·41-2·58) and NMSC (HR 0·70, 95% CI 0·47-1·05). Among participants aged over 60 years at baseline, we found statistically significant lower risks of all cancers and NMSC among FLG mutation carriers.CONCLUSIONS: The only significant associations between FLG loss-of-function mutations and cancer were in subgroup analyses.

AB - BACKGROUND: Loss-of-function mutations in the filaggrin gene (FLG) could have opposing effects on cancer risk, as mutations are associated with both 10% higher serum vitamin D levels, which may protect against cancer, and with impaired skin barrier function, which may lead to higher cancer susceptibility.OBJECTIVES: To investigate the association of the FLG genotype and cancer types in four population-based cohorts.METHODS: A total of 13,376 individuals were genotyped for FLG mutations. Information on cancer was obtained from the Danish Cancer Registry. Persons with a history of cancer at baseline were excluded from prospective analyses.RESULTS: There were 1339 incident cancers (median follow-up 11·4 years). The hazard ratios (HRs) and 95% confidence intervals (CIs) for FLG mutation carriers vs. wild types were: for any cancer (HR 0·95, 95% CI 0·78-1·16), any cancer excluding nonmelanoma skin cancer (NMSC) (HR 1·05, 95% CI 0·84-1·31), head and neck cancer (HR 1·72, 95% CI 0·71-4·15), colorectal cancer (HR 0·82, 95% CI 0·44-1·52), bronchus and lung cancer (HR 1·34, 95% CI 0·77-2·33), breast cancer (HR 0·58, 95% CI 0·30-1·14), uterine cancer (HR 0·42, 95% CI 0·06-3·10), prostate cancer (HR 1·09, 95% CI 0·61-1·94), urinary cancer (HR 1·30, 95% CI 0·51-3·29), malignant melanoma (HR 1·03, 95% CI 0·41-2·58) and NMSC (HR 0·70, 95% CI 0·47-1·05). Among participants aged over 60 years at baseline, we found statistically significant lower risks of all cancers and NMSC among FLG mutation carriers.CONCLUSIONS: The only significant associations between FLG loss-of-function mutations and cancer were in subgroup analyses.

U2 - 10.1111/bjd.12969

DO - 10.1111/bjd.12969

M3 - Journal article

C2 - 24628370

VL - 171

SP - 1407

EP - 1414

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 6

ER -

ID: 137429510